Compare KB Financial Group, Inc. (KB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Sanofi SA — how do they compare? KB Financial Group, Inc. trades at $123.99 (market cap $42.62B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.2× KB Financial Group, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Sanofi SA for 94 Days on average.
| KB | SNY | |
|---|---|---|
Market Cap | $42.62B | $95.18B |
Volume | 164,291 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $132.88 | $52.34 |
52-Week Low | $77.50 | $39.51 |
Typical Hold Time | 33 Days | 94 Days |
Enterprise Value | $215.53T | $114.48B |
Dividend Yield | 2.71% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $122.78, down 1.56% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with consistent earnings beats, growing revenue from $21.23T to $22.37T projected for 2026, and improving profit margins reaching 28.09%. Recent analyst coverage shows 33% buy ratings with positive momentum commentary from multiple financial outlets.
The outlook remains positive given KB's attractive valuation at 9.68 P/E and 0.94 P/B, coupled with sustained earnings growth. Key risks include market volatility and the company's significant investment outflows. Analyst consensus leans neutral with 67% hold ratings, suggesting cautious optimism for this value-oriented financial stock.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
